Press Releases
* Please note that the news release contains the content at the time of the announcement and may differ from the latest information.
Real Tech Fund conducts gene analysis in research and medical fields
Invested in "Ameliev Co., Ltd."
Euglena Investment Co., Ltd.
Euglena Investment Co., Ltd. (Headquarters: Minato-ku, Tokyo, Representative: Akihiko Nagata) is a new investment destination for the venture capital fund "Real Tech Fund", Amelieff Corporation (hereinafter referred to as Amelieff), which conducts genetic analysis in the research and medical fields. We would like to inform you that we have invested in (Company).
Recent advances in analytical equipment have made it possible to obtain vast amounts of genetic information at low cost, and it is expected that genetic information will be used for the prevention and treatment of diseases.
Ameliev possesses highly specialized gene analysis technology, and provides research institutes and medical institutions as customers for contract analysis of genetic information, system development for analyzing genetic information, and training services related to gene analysis. It is a venture company. Ameliev will utilize its gene analysis technology to enable the selection of treatment methods and drugs that can be expected to have high therapeutic effects and suppression of side effects according to the genetic characteristics of each individual, and to use the accumulated knowledge as the mechanism of the disease. We aim to realize a richer and healthier human society by utilizing it for elucidation and development of new drugs.
This time, Real Tech Fund will provide management support such as investment, business development support, and fund procurement support to Ameliev. With the investment and support, Ameliev will further expand its business development in the medical field. In the future, we plan to promote the use of gene analysis technology in the healthcare field.
The details are as follows.
About investment and support for Ameliev Co., Ltd.
■ About the outline and support contents of Ameliev
| name | : Ameliev Co., Ltd. |
| Date of establishment | : March 8, 2010 |
| Representative | : President and CEO Masao Yamaguchi |
| Capital | : 30 million yen |
| Street address | : 1-12-12 Kanda, Chiyoda-ku, Tokyo |
| Description of Business | : Life information analysis and analysis system development in the research and medical fields |
| HP | : Http://amelieff.jp/ |
| support | : Hands-on management support (business development support in the medical field, fund procurement support, etc.) |
| Investment date | : January 2016 |
■ About Real Tech Fund (HP: www.euglena-investment.jp)
Our 100% subsidiary of Euglena Investment, SMBC Nikko Securities, Ribanesu "Limited Liability Company was founded three companies Euglena in venture capital funds that SMBC Nikko Ribanesu capital" to management and operation, the investment development of the real tech venture as the main purpose is. With a total of 17 participating companies and a fund size of 5.5 billion yen (increasing), it is one of the largest real tech-specialized funds in Japan. We are investing in and nurturing real-tech ventures together with each operating company that is an investor.
Investors: Euglena Investment Co., Ltd., Revanes Co., Ltd., SMBC Nikko Securities Co., Ltd., Nippon Tobacco Industry Co., Ltd., Mitsui Real Estate Co., Ltd., Yoshinoya Holdings Co., Ltd., Rohto Pharmaceutical Co., Ltd., Kanetsu Co., Ltd., Dentsu Co., Ltd., Tokyo Century Lease Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Aizawa Securities Co., Ltd., Shimizu Construction Co., Ltd., Sumitomo Mitsui Banking Corporation, ANA Holdings Co., Ltd., THK Co., Ltd., Toyo Aluminum Co., Ltd. (17 companies in total)
-Contact for inquiries from the press-
Euglena Co., Ltd. Public Relations and IR Division